Palo Alto Investors, LLC Buys Immunogen Inc, Revance Therapeutics Inc, Intra-Cellular Therapies Inc, Sells Immunomedics Inc, Alder BioPharmaceuticals Inc, Celgene Corp

• New Purchases: IMGN, RVNC, ITCI,
• Added Positions: CLVS, FOLD,
• Reduced Positions: ABMD, BMRN, UTHR, ACAD, ALXN, INSM, SAGE, ALGN, STAA, KPTI, EPZM, AIMT, MNTA, VNDA, WMGI, PBYI, AMAG, RIGL, PRTA,
• Sold Out: IMMU, ALDR, CELG, ALIM,

For the details of Palo Alto Investors, LLC's stock buys and sells, go to https://www.gurufocus.com/guru/palo+alto+investors%2C+llc/current-portfolio/portfolio

1. Biomarin Pharmaceutical Inc (BMRN) - 2,021,136 shares, 9.44% of the total portfolio. Shares reduced by 8.53%
2. Insmed Inc (INSM) - 6,848,760 shares, 9.03% of the total portfolio. Shares reduced by 5.4%
3. Epizyme Inc (EPZM) - 6,145,945 shares, 8.35% of the total portfolio. Shares reduced by 3.28%
4. Staar Surgical Co (STAA) - 3,778,938 shares, 7.34% of the total portfolio. Shares reduced by 2.87%
5. Immunogen Inc (IMGN) - 5,923,195 shares, 6.92% of the total portfolio. New Position

Palo Alto Investors, LLC initiated holding in Immunogen Inc. The purchase prices were between $2.25 and $5.8, with an estimated average price of $3.45. The stock is now traded at around $6.80. The impact to a portfolio due to this purchase was 6.92%. The holding were 5,923,195 shares as of .

Palo Alto Investors, LLC initiated holding in Revance Therapeutics Inc. The purchase prices were between $11.66 and $20.15, with an estimated average price of $15.6. The stock is now traded at around $25.33. The impact to a portfolio due to this purchase was 0.08%. The holding were 88,590 shares as of .

Palo Alto Investors, LLC initiated holding in Intra-Cellular Therapies Inc. The purchase prices were between $7.76 and $38.49, with an estimated average price of $12.45. The stock is now traded at around $22.84. The impact to a portfolio due to this purchase was 0.07%. The holding were 37,400 shares as of .

Palo Alto Investors, LLC sold out a holding in Immunomedics Inc. The sale prices were between $13.54 and $21.77, with an estimated average price of $17.78.

Palo Alto Investors, LLC sold out a holding in Alder BioPharmaceuticals Inc. The sale prices were between $18.86 and $18.93, with an estimated average price of $18.89.

Palo Alto Investors, LLC sold out a holding in Celgene Corp. The sale prices were between $97.62 and $110.41, with an estimated average price of $105.2.

Palo Alto Investors, LLC sold out a holding in Alimera Sciences Inc. The sale prices were between $3.3 and $9.44, with an estimated average price of $5.96.